Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 3/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28366142 | 0.84 | ALDH1A1 (0.68) | ALDH1A1KMT2AMEN1L3MBTL1KDM4E | |
| SCHEMBL28366172 | 0.84 | ALDH1A1 (0.72) | ALDH1A1KMT2AMEN1L3MBTL1KDM4E | |
| SCHEMBL28362474 | 0.84 | ALDH1A1 (0.72) | ALDH1A1KMT2AMEN1L3MBTL1KDM4E | |
| SCHEMBL486145 | 0.84 | ALDH1A1 (1.00) | ALDH1A1KMT2AMEN1L3MBTL1KDM4E | |
| SCHEMBL486053 | 0.83 | ALDH1A1 (0.71) | ALDH1A1KMT2AMEN1L3MBTL1KDM4E | |
| SCHEMBL486421 | 0.82 | KMT2A (0.67) | ALDH1A1KMT2AMEN1L3MBTL1KDM4E | |
| SCHEMBL486240 | 0.81 | RECQL (0.74) | ALDH1A1KMT2AMEN1L3MBTL1KDM4E | |
| SCHEMBL28362330 | 0.80 | L3MBTL1 (1.00) | ALDH1A1KMT2AMEN1L3MBTL1KDM4E | |
| SCHEMBL28366141 | 0.78 | TSHR (0.64) | ALDH1A1KMT2AMEN1L3MBTL1KDM4E | |
| SCHEMBL11747295 | 0.76 | KMT2A (0.71) | ALDH1A1KMT2AMEN1L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2145884-B1 | INDOLEDIONE DERIVATIVE | MSD KK (JP) | 2014-08-06 | — | — | EP | disclosed |
| US-8106086-B2 | Indoledione derivative | MSD K.K. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-20100056597-A1 | INDOLEDIONE DERIVATIVE | MSD K.K. (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2145884-A1 | INDOLEDIONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056597-A1 | INDOLEDIONE DERIVATIVE | LIPE, IDO1, ADRA1A | ALDH1A1 303/4885KMT2A 776/4885MEN1 2086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.